1Lan GK, Carman WF, Locarnini SA, et al. Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective[J]. J Gastroenterol Hepatol, 1999, 14(1) :3 - 12.
2Chisari FV, Ferraric C. Hepatitis B virus immunopathogenesis[J]. Annu Rev Immunol, 1995, 13:29-60.
3Davis GL. Hepatitis B: diagnosis and treatment[J]. South Med J, 1997, 90(9) :866 - 871.
4Tompkins WA. Immunomodulation and therapeutic effects of oral use of interferon-alpha: mechanism of action[J]. J Interferon Cytokine Res, 1999, 19(8) :817 - 828.
5Robek MD, Wieland SF, Chisari FV. Inhibition of hepatitis B virus replication by interferon requires proteasome activity [J]. J Virol, 2002, 76(7) :3570- 3574.
6Seow HF. Pathogen interactions with cytokines and host defence: an overview[J]. Vet Immunol Immunopathol, 1998,63(1/2): 139 - 148.
7Alexander GJ. Immunology of hepatitis B virus infection [J]. Br Med Bull, 1990, 46(2) :354- 367.
8Barber GN. Host defense, viruses and apoptosis[J]. Cell Death Differ, 2001, 8(2):113- 126.
9Schultz U, Chisari FV. Recombinant duck interferon gamma inhibits duck hepatitis B virus replication in primary hepatocytes[J]. J Virol, 1999, 73(4): 3162 - 3168.
10Heise T, Guidotti LG, Cavanaugh VJ, et al. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice[J].J Virol, 1999, 73(1):474-481.
